Aliases & Classifications for Uterine Anomalies

MalaCards integrated aliases for Uterine Anomalies:

Name: Uterine Anomalies 57
Uterine Diseases 55 43 44 73
Uterine Disease 12 15
Uterine Abnormality 55

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
uterine anomalies:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM 57 192000
Disease Ontology 12 DOID:345
ICD10 33 N85.9
ICD9CM 35 621.9
MeSH 44 D014591
NCIt 50 C26907
MedGen 42 C0266383
SNOMED-CT via HPO 69 263681008 31401003
UMLS 73 C0042131

Summaries for Uterine Anomalies

MedlinePlus : 43 The uterus, or womb, is the place where a baby grows when a woman is pregnant. The first sign of a problem with the uterus may be bleeding between periods or after sex. Causes can include hormones, thyroid problems, fibroids, polyps, cancer, infection, or pregnancy. Treatment depends on the cause. Sometimes birth control pills treat hormonal imbalances. If a thyroid problem is the cause, treating it may also stop the bleeding. If you have cancer or hyperplasia, an overgrowth of normal cells in the uterus, you may need surgery. With two other uterine problems, tissue that normally lines the uterus grows where it is not supposed to. In endometriosis, it grows outside the uterus. In adenomyosis, it grows in the uterus's outside walls. Pain medicine may help. Other treatments include hormones and surgery.

MalaCards based summary : Uterine Anomalies, also known as uterine diseases, is related to endometriosis and vaginitis, and has symptoms including pelvic pain An important gene associated with Uterine Anomalies is SERPINH1 (Serpin Family H Member 1), and among its related pathways/superpathways are Influenza A and NF-KappaB Family Pathway. The drugs Levonorgestrel and Medroxyprogesterone acetate have been mentioned in the context of this disorder. Affiliated tissues include the uterus, cervix and testes, and related phenotypes are bicornuate uterus and cardiovascular system

Disease Ontology : 12 A female reproductive system disease that is located in the uterus.

Description from OMIM: 192000

Related Diseases for Uterine Anomalies

Diseases in the Uterine Anomalies family:

Uterine Inflammatory Disease

Diseases related to Uterine Anomalies via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 238)
# Related Disease Score Top Affiliating Genes
1 endometriosis 30.4 CXCL8 CYP19A1 ESR1 IL6
2 vaginitis 30.1 CXCL8 ESR1 IL1B IL6 SERPINH1
3 placenta disease 26.8 AFP CSH1 CSH2 CXCL8 EPHA1 IL1B
4 osteoporotic fracture 10.9 ESR1 IL6
5 endometriosis of ovary 10.9 CYP19A1 ESR1 HNF1B
6 juvenile nasopharyngeal angiofibroma 10.9 CYP19A1 ESR1 TLR9
7 scorpion envenomation 10.9 IL6 TNF
8 acrorenal-mandibular syndrome 10.9
9 preterm premature rupture of the membranes 10.9 CXCL8 IL6 SERPINH1
10 recurrent corneal erosion 10.8 CXCL8 IL1B IL6
11 bagassosis 10.8 CXCL8 IL1B IL6
12 cold agglutinin disease 10.8 CRP IL6
13 leukomalacia 10.8 IL6 TNF
14 systemic onset juvenile idiopathic arthritis 10.8 IL1B TNF
15 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL6 TNF
16 stomach disease 10.7 CXCL8 IL1B TLR9
17 vulvar vestibulitis syndrome 10.7 ESR1 IL1B TNF
18 eye lymphoma 10.7 IL6 TLR9
19 streptococcal toxic-shock syndrome 10.7 CXCL8 IL6 TNF
20 opisthorchiasis 10.7 AFP CXCL8 IL1B
21 staphylococcal toxic shock syndrome 10.7 IL1B TNF
22 viral pneumonia 10.7 CRP IL6 TLR9
23 extrinsic allergic alveolitis 10.7 CXCL8 IL1B IL6
24 testicular trophoblastic tumor 10.7 CSH1 CSH2
25 meconium aspiration syndrome 10.7 CXCL8 IL6 TNF
26 laryngitis 10.7 IL1B IL6 TNF
27 placenta praevia 10.7 EPHA1 SERPINH1
28 acute vascular insufficiency of intestine 10.7 IL1B IL6 TNF
29 poems syndrome 10.7 IL1B IL6 TNF
30 transverse myelitis 10.7 CXCL8 IL6 TNF
31 osteosclerotic myeloma 10.7 IL1B IL6 TNF
32 haemophilus influenzae 10.7 CXCL8 IL1B TNF
33 stachybotrys chartarum 10.7 IL1B IL6 TNF
34 crohn's colitis 10.7 CXCL8 IL1B TNF
35 cytomegalovirus infection 10.7 CXCL8 IL6 TNF
36 eales disease 10.7 IL1B IL6 TNF
37 uremic pruritus 10.7 CRP IL1B IL6
38 esophagitis 10.7 CXCL8 IL1B IL6
39 dental pulp disease 10.7 CXCL8 IL1B TNF
40 autoimmune myocarditis 10.7 IL1B TNF
41 fasciitis 10.7 CXCL8 IL6 TNF
42 joint disorders 10.7 IL1B IL6 TNF
43 nose disease 10.7 CXCL8 TLR9 TNF
44 aseptic meningitis 10.7 CXCL8 IL1B TNF
45 acute cystitis 10.7 CRP CXCL8 IL6
46 commensal bacterial infectious disease 10.7 IL1B IL6 TNF
47 aphthous stomatitis 10.7 IL1B IL6 TNF
48 human immunodeficiency virus infectious disease 10.7 IL6 TLR9 TNF
49 upper respiratory tract disease 10.7 CXCL8 TLR9 TNF
50 dengue shock syndrome 10.7 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Uterine Anomalies:



Diseases related to Uterine Anomalies

Symptoms & Phenotypes for Uterine Anomalies

Symptoms via clinical synopsis from OMIM:

57
GU:
uterine anomalies
uterus arcuatus
uterus bicornis unicollis


Clinical features from OMIM:

192000

Human phenotypes related to Uterine Anomalies:

32
# Description HPO Frequency HPO Source Accession
1 bicornuate uterus 32 HP:0000813

UMLS symptoms related to Uterine Anomalies:


pelvic pain

MGI Mouse Phenotypes related to Uterine Anomalies:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.02 ESR1 SERPINH1 IL1B TNF IL6 CRP
2 growth/size/body region MP:0005378 9.93 ESR1 PNLIP HNF1B SERPINH1 IL1B IL6
3 adipose tissue MP:0005375 9.91 PNLIP TNF IL6 OXT CYP19A1 PGF
4 digestive/alimentary MP:0005381 9.86 PNLIP SERPINH1 TLR9 TNF IL6 OXT
5 homeostasis/metabolism MP:0005376 9.8 HNF1B IL1B TLR9 TNF IL6 AFP
6 liver/biliary system MP:0005370 9.17 ESR1 PNLIP HNF1B IL6 TNF AFP

Drugs & Therapeutics for Uterine Anomalies

Drugs for Uterine Anomalies (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 625)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levonorgestrel Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 797-63-7, 17489-40-6 13109
2
Medroxyprogesterone acetate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 71-58-9
3
Iodine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 7553-56-2 807
4
Povidone Approved Phase 4,Phase 3,Not Applicable 9003-39-8
5
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
6
Norethindrone Approved Phase 4,Phase 3,Phase 2,Not Applicable 68-22-4 6230
7
Azithromycin Approved Phase 4,Phase 3,Not Applicable 83905-01-5 55185 447043
8
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 564-25-0 54671203
9
Lymecycline Approved, Investigational Phase 4 992-21-2 5280963
10
Tetracycline Approved, Vet_approved Phase 4 60-54-8 5353990
11
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
12 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
13
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
14
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
15
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable 657-24-9 14219 4091
16
Tranexamic Acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 1197-18-8 5526
17
Copper Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7440-50-8 27099
18
Misoprostol Approved Phase 4,Phase 3,Not Applicable 59122-46-2 5282381
19
Acetaminophen Approved Phase 4,Phase 2 103-90-2 1983
20
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
21
Tamoxifen Approved Phase 4,Phase 3,Phase 2 10540-29-1 2733526
22
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
23
Hyaluronic acid Approved, Vet_approved Phase 4,Not Applicable 9004-61-9 53477741
24
Ethinyl Estradiol Approved Phase 4,Phase 2,Phase 1,Not Applicable,Early Phase 1 57-63-6 5991
25
Clindamycin Approved, Vet_approved Phase 4,Not Applicable 18323-44-9 29029
26
Dalteparin Approved Phase 4,Phase 3 9005-49-6
27
Enoxaparin Approved Phase 4 9005-49-6 772
28
Heparin Approved, Investigational Phase 4,Phase 3 9005-49-6 772 46507594
29
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
30
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
31
Mefenamic acid Approved Phase 4,Phase 3 61-68-7 4044
32
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
33
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
34
Ibuprofen Approved Phase 4 15687-27-1 3672
35
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
36
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 137-58-6 3676
37
Morphine Approved, Investigational Phase 4,Early Phase 1 57-27-2 5288826
38
Aprepitant Approved, Investigational Phase 4 170729-80-3 151165 6918365
39
Fosaprepitant Approved Phase 4 172673-20-0 219090
40
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
41
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
42
Ethanol Approved Phase 4,Not Applicable 64-17-5 702
43
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
44
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
45
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
46
Etonogestrel Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 54048-10-1 40976 6917715
47
Cefazolin Approved Phase 4,Not Applicable 25953-19-9 656510 33255
48
Chloroprocaine Approved Phase 4 133-16-4 8612
49
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
50
Anastrozole Approved, Investigational Phase 4,Phase 1,Phase 2 120511-73-1 2187

Interventional clinical trials:

(show top 50) (show all 1978)
# Name Status NCT ID Phase Drugs
1 A Study Comparing Mirena and Systemic Progestin for Endometrial Hyperplasia Unknown status NCT01074892 Phase 4 Provera (medroxyprogesterone/progestin);Provera (medroxyprogesterone)
2 CavatermTM vs TCRE in Women With DUB Unknown status NCT00549159 Phase 4
3 Preoperative Vaginal Cleansing With Povidone Iodine and the Risk of Post Cesarean Endometritis Unknown status NCT02693483 Phase 4 10% povidone iodine
4 A New Treatment Option for Heavy Menstrual Bleeding Unknown status NCT01715025 Phase 4 E2Nomac
5 Pretreatment With Norethindrone Acetate Prior to Levonorgestrel IUS Insertion for Heavy Menstrual Bleeding Unknown status NCT01391052 Phase 4 Norethindrone acetate pretreatment
6 Surgical Treatment To Greater Anterior Vaginal Prolapse Unknown status NCT00676325 Phase 4
7 Comparative Study of Mesh Versus No Mesh in Prolapse Surgery Unknown status NCT00153257 Phase 4
8 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Unknown status NCT02837926 Phase 4
9 Time to Eradication of Mycoplasma Genitalium and Chlamydia Trachomatis After Treatment Commenced Unknown status NCT01661985 Phase 4 Azithromycin;Doxycycline;lymecycline
10 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
11 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo;Estradiol or Placebo
12 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
13 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
14 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
15 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
16 Efficacy of 17 Alpha-hydroxyprogesterones Caproate for the Prevention of Preterm Delivery Completed NCT00331695 Phase 4 17 alpha-hydroxyprogesterones caproate
17 Implantation Failure and PGD Completed NCT00547781 Phase 4
18 Role of Intrauterine Cornual Block in Combination With Direct Cervical Block in Outpatient Endometrial Ablation Completed NCT01808898 Phase 4
19 Apoptotic Signaling Pathways in Rats With Endometrial Hyperplasia Completed NCT02872818 Phase 4 17β estradiol hemihydrate;Metformin;medroxyprogesterone acetate
20 Management of Initial Bleeding/Spotting Associated With the Levonorgestrel-releasing Intrauterine System (MIRENA) Completed NCT01295294 Phase 4 Tranexamic acid;Mefenamic acid;Placebo;Mirena (Levonorgestrel IUS, BAY86-5028)
21 Endometrial Ablation With Non-hysteroscopic Methods Completed NCT01173965 Phase 4
22 DMPA & High Dose Oral Progestin (MPA) Tablets in Outpatient Treatment of Acute Excessive Vaginal Bleeding Completed NCT01148420 Phase 4 Medroxyprogesterone 17-Acetate;medroxyprogesterone acetate
23 Comparison Between Transvaginal Mesh and Traditional Surgery for Pelvic Organ Prolapse Completed NCT00566917 Phase 4
24 Posterior IVS Versus Sacrospinous Suspension in Vaginal Vault Prolapse Repair Completed NCT00153231 Phase 4
25 Local Infiltration Analgesia With Ropivacaine in Posterior Vaginal Wall Prolapse:a Randomized, Double-Blind Study Completed NCT00769054 Phase 4 Ropivacaine;Isotonic NaCl
26 Clinical Assessment of the Total Vaginal Mesh Technique for Treatment of Genital Prolapse Completed NCT00196495 Phase 4
27 Does Preoperative Vaginal Preparation With Povidone-iodine Before Cesarean Delivery Reduce the Risk of Endometritis? Completed NCT01437228 Phase 4 povidone- iodine solution.;placebo
28 Doxycycline Prophylaxis at Vacuum Aspiration Trial Completed NCT00547170 Phase 4 Doxycycline pre-operatively;Doxycycline post-operatively
29 Copper IUD Treatment Observation Study Completed NCT02519231 Phase 4 Naproxen;Placebo
30 Chances for Success of CavatermTM Surgery as a Function of Uterus Probe Length Completed NCT01436903 Phase 4
31 Lysteda Pediatric Research Equity Act (PREA) Pharmacokinetic Study in Adolescent Females With Heavy Menstrual Bleeding Completed NCT01190150 Phase 4 tranexamic acid
32 Medical Therapy Versus Radiofrequency Endometrial Ablation in the Initial Treatment of Menorrhagia Completed NCT01165307 Phase 4 Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills;Naproxen sodium pills
33 Bleeding Pattern and User Satisfaction During Second Consecutive MIRENA® in Contraception and Treatment of Menorrhagia Completed NCT00393198 Phase 4 Levonorgestrel (Mirena, BAY86-5028);Cytotec;Placebo
34 Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients Completed NCT03032848 Phase 4 Conjugated Estrogen;Promestriene;Estriol;Vaginal Moisturizer - Cream
35 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System Completed NCT00094536 Phase 4
36 Efficacy Study of Vaginal Mesh for Anterior Prolapse Completed NCT00557882 Phase 4
37 The Assessment of Tranexamic Acid in Women With Menorrhagia Who Have Bleeding Disorders Completed NCT00904709 Phase 4 tranexamic acid
38 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
39 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
40 Effectiveness of IV Acetaminophen and IV Ibuprofen in Reducing Post Procedural Pain in the UFE Procedure Completed NCT02227316 Phase 4 IV Ibuprofen;IV Acetaminophen;Intravenous placebo/Intravenous placebo
41 Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer Completed NCT01988376 Phase 4
42 The Effect of Nutritional Counseling for Cancer Patients Completed NCT01962272 Phase 4
43 Efficacy Study of Vaginal Mesh for Prolapse Completed NCT00475540 Phase 4
44 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
45 Intravenous or Intra-abdominal Local Anesthetics for Postoperative Pain Management. Completed NCT01492179 Phase 4 Normal saline;Intravenous Lidocaine;Intra-abdominal Lidocaine
46 Fosaprepitant Versus Aprepitant in the Prevention of Chemotherapy Induced Nausea and Vomiting Completed NCT01432015 Phase 4 fosaprepitant;aprepitant
47 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
48 Immune Response to the Human Papillomavirus Vaccine in Young Women With Inflammatory Bowel Disease Completed NCT01034358 Phase 4
49 Management of Cervical Intraepithelial Neoplasia Grade 2 Completed NCT00733109 Phase 4
50 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4

Search NIH Clinical Center for Uterine Anomalies

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: uterine diseases

Genetic Tests for Uterine Anomalies

Anatomical Context for Uterine Anomalies

The Foundational Model of Anatomy Ontology organs/tissues related to Uterine Anomalies:

19
The Uterus

MalaCards organs/tissues related to Uterine Anomalies:

41
Cervix, Testes, Lymph Node, Uterus, T Cells, Thyroid, Lung

Publications for Uterine Anomalies

Articles related to Uterine Anomalies:

(show top 50) (show all 101)
# Title Authors Year
1
Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. ( 29055072 )
2018
2
Re: Outcome of assisted reproduction in women with congenital uterine anomalies: a prospective observational study. M. Prior, A. Richardson, S. Asif, L. Polanski, M. Parris-Larkin, J. Chandler, L. Fogg, P. Jassal, J. G. Thornton, N. J. Raine-Fenning. Ultrasound Obstet Gynecol 2018; 51: 110-117. ( 29297614 )
2018
3
Undescended or absent ovary without uterine anomalies: systematic review and a single center's experience. ( 28116887 )
2017
4
Fundus Thickness Assessment by 3D Transvaginal Ultrasound Allows Metrics-Based Diagnosis and TreatmentA of Congenital Uterine Anomalies. ( 26085458 )
2017
5
The association between obstetrical history and preterm birth in women with uterine anomalies. ( 28651449 )
2017
6
Classification of Uterine Anomalies by 3-Dimensional Ultrasonography Using ESHRE/ESGE Criteria: Interobserver Variability. ( 28847221 )
2017
7
A Case of Simultaneous Benign Metastasizing Leiomyomas and Disseminated Peritoneal Leiomyomatosis Following Endoscopic Power Morcellation for Uterine Disease. ( 27748666 )
2017
8
Endometrial cancer with congenital uterine anomalies: 3 case reports and a literature review. ( 28118070 )
2017
9
Diagnosis and Management of Congenital Uterine Anomalies in Pregnancy. ( 28304417 )
2017
10
Juvenile Cystic Adenomyoma Mimicking a Uterine Anomaly: a Report of Two Cases. ( 28416935 )
2017
11
Hysterectomy for Benign Uterine Disease. ( 27146592 )
2016
12
Training Performance in Diagnosis of Congenital Uterine Anomalies With 3-Dimensional Sonography: A Learning Curve Cumulative Summation Analysis. ( 27872415 )
2016
13
Undescended or absent ovary without uterine anomalies: systematic review and a single-center experience. ( 27727203 )
2016
14
Vulvovaginal laceration as a risk factor for uterine disease in postpartum dairy cows. ( 27016827 )
2016
15
The effect of puerperal uterine disease on histopathologic findings and mRNA expression of proinflammatory cytokines of the endometrium in dairy cows. ( 26810831 )
2016
16
Early Experience of Robotic Hysterectomy for Treatment of Benign Uterine Disease. ( 27643518 )
2016
17
Uterine disease and its effect on subsequent reproductive performance of dairy cattle: a comparison of two cow-side diagnostic methods. ( 27450885 )
2016
18
Malignant uterine disease with concurrent myometrial contraction at MRI: a possible source of overstaging. ( 27818552 )
2016
19
Congenital Uterine Anomalies and Uterine Rupture. ( 26990544 )
2016
20
Longitudinal vaginal septa with associated uterine anomalies: a case series. ( 25349941 )
2015
21
Pictorial Review of Complications of Uterine Anomalies. ( 26601928 )
2015
22
Does surgery improve live birth rates in patients with recurrent miscarriage caused by uterine anomalies? ( 25058627 )
2015
23
Reliability of the European Society of Human Reproduction and Embryology/European Society for Gynaecological Endoscopy and American Society for Reproductive Medicine classification systems for congenital uterine anomalies detected using three-dimensional ultrasonography. ( 26158905 )
2015
24
Association between HSD17B1 rs605059 polymorphisms and the risk of uterine diseases: a systemic review and meta-analysis. ( 26261478 )
2015
25
Pattern of Congenital Uterine Anomalies Among Infertile Women in Southwest Nigeria. ( 27678894 )
2015
26
Usefulness of three dimensional transvaginal ultrasonography and hysterosalpingography in diagnosing uterine anomalies. ( 25011216 )
2014
27
MRI appearances of benign uterine disease. ( 25017452 )
2014
28
Polycystic ovarian syndrome and congenital uterine anomalies: the hidden common player. ( 24615567 )
2014
29
Laparoendoscopic single-site versus conventional laparoscopic-assisted vaginal hysterectomy for benign or pre-invasive uterine disease. ( 25106721 )
2014
30
A classification of congenital uterine anomalies predicting pregnancy outcomes. ( 24773088 )
2014
31
Differential endometrial cell sensitivity to a cholesterol-dependent cytolysin links Trueperella pyogenes to uterine disease in cattle. ( 24478394 )
2014
32
Mucin 1 and cytokines mRNA in endometrium of dairy cows with postpartum uterine disease or repeat breeding. ( 24576715 )
2014
33
Clinical implications of congenital uterine anomalies: a meta-analysis of comparative studies. ( 25444500 )
2014
34
Routes of hysterectomy in women with benign uterine disease in the Vancouver Coastal Health and Providence Health Care regions: a retrospective cohort analysis. ( 25485254 )
2014
35
An autopsy report on a ruptured rudimentary horn (uterine anomaly) with ectopic pregnancy. ( 23265443 )
2013
36
Associations among serum pro- and anti-inflammatory cytokines, metabolic mediators, body condition, and uterine disease in postpartum dairy cows. ( 24209779 )
2013
37
Drivers of post-partum uterine disease in dairy cattle. ( 23962215 )
2013
38
The effect of puerperal uterine disease on uterine involution in cows assessed by Doppler sonography of the uterine arteries. ( 24275717 )
2013
39
Evaluation of cytokine expression by blood monocytes of lactating Holstein cows with or without postpartum uterine disease. ( 21924475 )
2012
40
When do we need to perform laparotomy for benign uterine disease? Factors involved with conversion in vaginal hysterectomy. ( 21955358 )
2012
41
Evaluation of peripartal calcium status, energetic profile, and neutrophil function in dairy cows at low or high risk of developing uterine disease. ( 23021755 )
2012
42
The utility of serum CA-125 in predicting extra-uterine disease in apparent early-stage endometrial cancer. ( 21918977 )
2012
43
Tackling uterine disease in cattle. ( 22544588 )
2012
44
Preoperative CA-125 predicts extra-uterine disease and survival in uterine papillary serous carcinoma patients. ( 22865295 )
2012
45
Placenta accreta: pathogenesis of a 20th century iatrogenic uterine disease. ( 22284667 )
2012
46
Congenital uterine anomalies and adverse pregnancy outcomes. ( 21907963 )
2011
47
AAGL position statement: route of hysterectomy to treat benign uterine disease. ( 21059487 )
2011
48
Association between uterine disease and indicators of neutrophil and systemic energy status in lactating Holstein cows. ( 20630210 )
2010
49
A prospective randomized comparison of vaginal hysterectomy, laparoscopically assisted vaginal hysterectomy, and total laparoscopic hysterectomy in women with benign uterine disease. ( 19926201 )
2010
50
Plasma PGF 2 alpha metabolite levels in cats with uterine disease. ( 19748114 )
2009

Variations for Uterine Anomalies

Expression for Uterine Anomalies

Search GEO for disease gene expression data for Uterine Anomalies.

Pathways for Uterine Anomalies

Pathways related to Uterine Anomalies according to GeneCards Suite gene sharing:

(show all 36)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.74 CXCL8 IL1B IL6 TLR9 TNF
2
Show member pathways
12.66 IL1B IL6 PGF TLR9 TNF
3
Show member pathways
12.44 CSH1 CSH2 CXCL8 IL1B IL6 TNF
4
Show member pathways
12.29 CRP IL1B IL6 TNF
5
Show member pathways
12.28 CXCL8 IL1B IL6 TNF
6
Show member pathways
12.22 CXCL8 IL6 TLR9 TNF
7
Show member pathways
12.21 IL1B IL6 TLR9 TNF
8
Show member pathways
12.21 CXCL8 IL1B IL6 TNF
9 12.19 IL1B IL6 TLR9 TNF
10
Show member pathways
12.17 CXCL8 IL1B IL6 TNF
11
Show member pathways
12.16 IL1B IL6 TLR9 TNF
12 12.12 CXCL8 IL1B IL6 TNF
13
Show member pathways
12.05 CXCL8 IL1B IL6 TLR9 TNF
14 11.97 CXCL8 IL1B IL6 TNF
15 11.93 CXCL8 IL1B IL6 TNF
16 11.84 CXCL8 IL1B IL6 TNF
17 11.82 CXCL8 IL1B TNF
18 11.82 CXCL8 IL1B IL6 TNF
19 11.78 CXCL8 IL1B IL6
20 11.78 CXCL8 IL1B IL6 TNF
21 11.75 AFP CXCL8 IL6
22 11.69 CXCL8 IL1B IL6 TNF
23 11.66 IL1B IL6 TLR9 TNF
24 11.58 CXCL8 IL1B IL6 TNF
25
Show member pathways
11.56 CXCL8 IL1B IL6 TNF
26 11.45 CXCL8 IL1B IL6 TNF
27 11.32 IL1B IL6 TNF
28 11.31 CXCL8 IL1B IL6 TNF
29 11.27 IL1B IL6 TNF
30 11.24 IL1B IL6 TNF
31 11.21 IL1B IL6 TNF
32 11.21 CYP19A1 IL1B IL6 TNF
33 11